| Document |
Document Title |
|
WO/2011/101321A1 |
A description is given of 3-aminocarbonyl-substituted benzoylcyclohexanediones of the general formula (I) as herbicides. In this formula (I), R1 to R5 stand for radicals such as hydrogen, organic radicals such as alkyl, and other radic...
|
|
WO/2011/097712A1 |
Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (HDAC) moiety are disclosed. Hybrid molecule 3 ( 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalen
e-2-hydroxamic acid) wa...
|
|
WO/2011/058582A1 |
Described are bridged compounds of the formula (I), their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prod...
|
|
WO/2011/055843A1 |
Disclosed is a substance (a retinoid compound represented by the formula), which acts on a retinoic acid receptor that is a nuclear receptor. (In the formula, R1 and R2 each independently represents a group selected from among an NH2 gro...
|
|
WO/2011/056983A1 |
Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cyst...
|
|
WO/2011/023706A1 |
The present invention related to a process for the preparation of formula (I), wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen. (R)-2-phenyl propionic acid derivatives of the formula (I) are key intermediates in the synthesis of 5...
|
|
WO/2011/021209A1 |
The disclosure provides compounds of formula I and methods for preparation thereof. The compounds act as inhibitor of histone deacetylase.
|
|
WO/2010/133748A1 |
A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors a...
|
|
WO/2010/119877A1 |
Disclosed is a process for producing an amidine derivative having an ester bond, which is a compound highly useful as a substance having an anti-coagulation activity, on an industrial scale. Specifically disclosed is a process for produc...
|
|
WO/2010/115758A2 |
Compounds of the formula (I) in which the substituents have the meaning given in the description, processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi.
|
|
WO/2010/100475A1 |
The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embod...
|
|
WO/2010/097586A1 |
Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent =CH- or =N-; W is-CH=CH- Or -CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular...
|
|
WO/2010/072602A1 |
The invention relates to substituted amidine compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substituted amidine co...
|
|
WO/2010/066909A2 |
The present invention relates in general to a compound which is characterized by a formula selected from the following formulas A, B, C, D, E or F; or a pharmaceutically acceptable salt thereof. The present invention further relates to p...
|
|
WO/2010/065709A2 |
Disclosed are amino alkyl/aryl hydroxamic acid compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for degenerative diseases in mammal.
|
|
WO/2010/043904A2 |
The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient vorinostat. In particular it relates to a process for preparing vorinostat substantially free from impurities.
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/031750A1 |
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
|
|
WO/2010/009508A1 |
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
|
|
WO/2010/010174A1 |
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase...
|
|
WO/2009/113320A1 |
Provided is a new compound with excellent MMP inhibitory effect and reduced side-effects. The compound is a matrix metalloproteinase inhibitor with, as an active ingredient, the hydroxamic acid derivative represented by general formula (...
|
|
WO/2009/098515A1 |
The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient, vorinostat. In particular it relates to an efficient process for the preparation of vorinostat of high purity without the r...
|
|
WO/2009/067856A1 |
A histone deacetylase inhibitor, a composition in which the inhibitor is used as an active component and use thereof. The inhibitor has a structure of general formula (I), which is defined as that in the specification. The histone deacet...
|
|
WO/2009/055917A1 |
ABSTRACT OF THE DISCLOSURE This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharm...
|
|
WO/2009/055863A1 |
The present invention relates to desferoxamine conjugates, derivatives and analogues thereof. In particular, the present invention relates to desferoxamine conjugates, analogues and derivatives thereof, and methods for reducing levels of...
|
|
WO/2009/053808A2 |
Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acc...
|
|
WO/2009/047615A2 |
Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and comp...
|
|
WO/2009/035543A1 |
The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and n...
|
|
WO/2009/012656A1 |
Inhibitors for matrix metalloproteinases, pharmaceutical compositions containing them and their uses. The inhibitors for matrix metalloproteinases have the formula (I), wherein W, X1, X2, R1, R2 are as defined in the description. They ar...
|
|
WO/2009/008905A1 |
Compounds having the formula : (I) wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of phenoxy-acetic acids and analogs capable of inhibiting the lethal effects of infection by anthrax b...
|
|
WO/2008/154905A2 |
The application relates to compounds of general formula (I) Ar-[CH2]m-Z1-N(Z2-R2)-Z3-[C(O)]r-[CH2]n-Y1-[C(O)]s-Y2-R1, in which the variables can take the values specified in the application. In particularly preferred individual compounds...
|
|
WO/2008/154642A2 |
Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2008/154382A1 |
The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone...
|
|
WO/2008/147480A2 |
Compounds having the formula (I) wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 3 -phenyl-propionic acid and capable of inhibiting the lethal effects of infection by anthrax bacteri...
|
|
WO/2008/136976A2 |
Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer inductio...
|
|
WO/2008/122115A1 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable ...
|
|
WO/2008/115153A1 |
A process for preparing hydroxamic acids is provided. The process comprises reacting an aldehyde with a nitroso compound in the presence of a N-heterocyclic carbene (NHC) catalyst.
|
|
WO/2008/104755A1 |
A compound of formula (I) wherein R1 is C1-4 alkyl, allyl or propargyl; R2 is C1-6 alkyl, -(CH2)m-aryl or -(CH2)m-heteroaryl; R3 is H or C1-4 alkyl; R4 is C1-4 alkyl, -(CH2)n-aryl or -(CH2)n-heteroaryl; R5 is H, OH or C1-4 alkoxy; and m ...
|
|
WO/2008/097459A2 |
The invention is directed to compounds of formula (I): wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) have AT1 receptor antagonist activity ...
|
|
WO/2008/094592A1 |
Compounds having the formula (I), wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of aniline and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful...
|
|
WO/2008/074132A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
WO/2008/061866A1 |
A compound of general formula (I): A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition ...
|
|
WO/2008/040934A1 |
Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or m...
|
|
WO/2008/025965A2 |
The invention relates to retinoid compounds of one of the following formulae: Formula 6 a; R = H D1 R = Me (i) PaIa-CO2R' QC = H or Me) (ii)Imeta-CO2R' (R' = H or Me) (iii) ortho-CO2R' (R1 = H or Me) Formula 10 a,R = H b; R = Me (i) PaIa...
|
|
WO/2008/009264A1 |
The invention relates to the use of N,N'-dihydroxyamidine (I), N,N'-dihydroxyamidine ether (II), N,N'-dihydroxyamidine diether (III), N,N'-dihydroxyamidine ester (IV), N,N'-dihydroxyamidine diester (V) or 4-hydroxy-1,2,4-oxadiazoline (VI...
|
|
WO/2007/113644A2 |
The present invention relates to novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, ph...
|
|
WO/2007/077240A2 |
Stable complexes are described, formed by mono- and di-functional compounds bound to nanoparticles composed of various types of transition metal oxides and of metals useful in the production processes of different types of new materials ...
|
|
WO/2007/072179A2 |
The present invention relates to compounds, compositions thereof and methods to selectively treat fungal infections More particularly this invention relates to compounds, compositions thereof and methods for selectively enhancing fungal ...
|
|
WO/2007/069020A2 |
Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical c...
|
|
WO/2007/056469A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
